Imperial College London
Portrait Picture

MrMikaelSodergren

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Hepatopancreatobiliary Surgery
 
 
 
//

Contact

 

m.sodergren

 
 
//

Location

 

BN2/13Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ergisi:2023:10.1089/can.2021.0145,
author = {Ergisi, M and Erridge, S and Harris, M and Kawka, M and Nimalan, D and Salazar, O and Loupasaki, K and Ali, R and Holvey, C and Coomber, R and Usmani, A and Sajad, M and Beri, S and Hoare, J and Khan, SA and Weatherall, MW and Platt, M and Rucker, JJ and Sodergren, MH},
doi = {10.1089/can.2021.0145},
journal = {Cannabis and Cannabinoid Research},
pages = {557--566},
title = {An updated analysis of clinical outcome measures across patients from the UK medical cannabis registry},
url = {http://dx.doi.org/10.1089/can.2021.0145},
volume = {8},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Introduction: There is a growing body of literature supporting the efficacy of cannabis-based medicinal products (CBMPs). Despite an increase in prescribing globally, there is a paucity of high-quality clinical data on the efficacy of CBMPs for many conditions. This study aims to detail the changes in health-related quality of life (HRQoL) and associated clinical safety in patients prescribed CBMPs for any clinical indication from the UK Medical Cannabis Registry (UKMCR). Methods: An uncontrolled prospective case series of the UKMCR was analyzed. Primary outcomes included change from baseline in patient-reported outcome measures collected across all patients (the Generalized Anxiety Disorder Scale [GAD-7], EQ-5D-5L, and Sleep Quality Scale [SQS]) at 1, 3, and 6 months. Secondary outcomes included the self-reported incidence and severity of adverse events. Statistical significance was defined as p<0.050. Results: Three hundred twelve patients were included in the final analysis, with a mean age of 44.8. The most common primary diagnoses were chronic pain of undefined etiology (n=102, 32.7%), neuropathic pain (n=43, 13.8%), and fibromyalgia (n=31, 9.9%). Before enrolment, 112 (35.9%) patients consumed cannabis daily. The median cannabidiol and (-)-trans-Δ9-tetrahydrocannabinol doses prescribed at baseline were 20.0 mg (0.0-510.0 mg) and 3.0 mg (0.0-660.0 mg), respectively. Statistically significant improvements were observed in GAD-7, EQ-5D-5L Index, EQ-5D Visual Analog Scale and SQS scores at 1, 3, and 6 months (p<0.050). There were 94 (30.1%) reported adverse events, of which nausea (n=12, 3.8%), dry mouth (n=10, 3.2%), dizziness (n=7, 2.2%), and somnolence (n=7, 2.2%) were the most common. Conclusion: This study demonstrated CBMP treatment to be associated with a relatively low incidence of severe adverse events in the medium-term. Positive changes following treatment were observed in general, as well as anxiety and sleep-spe
AU  - Ergisi,M
AU  - Erridge,S
AU  - Harris,M
AU  - Kawka,M
AU  - Nimalan,D
AU  - Salazar,O
AU  - Loupasaki,K
AU  - Ali,R
AU  - Holvey,C
AU  - Coomber,R
AU  - Usmani,A
AU  - Sajad,M
AU  - Beri,S
AU  - Hoare,J
AU  - Khan,SA
AU  - Weatherall,MW
AU  - Platt,M
AU  - Rucker,JJ
AU  - Sodergren,MH
DO  - 10.1089/can.2021.0145
EP  - 566
PY  - 2023///
SN  - 2378-8763
SP  - 557
TI  - An updated analysis of clinical outcome measures across patients from the UK medical cannabis registry
T2  - Cannabis and Cannabinoid Research
UR  - http://dx.doi.org/10.1089/can.2021.0145
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35073160
UR  - https://www.liebertpub.com/doi/10.1089/can.2021.0145
UR  - http://hdl.handle.net/10044/1/100270
VL  - 8
ER  -
Download